Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 24:2022:3198590.
doi: 10.1155/2022/3198590. eCollection 2022.

A Novel Prognostic Model Based on Seven Necroptosis-Related miRNAs for Predicting the Overall Survival of Patients with Lung Adenocarcinoma

Xiaohua Hong  1 , Guangyao Wang  2 , Kai Pei  1 , Chunmei Mo  3 , Zhen Rong  3 , Guanglan Xu  2
Affiliations

A Novel Prognostic Model Based on Seven Necroptosis-Related miRNAs for Predicting the Overall Survival of Patients with Lung Adenocarcinoma

Xiaohua Hong et al. Biomed Res Int. .

Abstract

Lung adenocarcinoma (LUAD) remains one of the leading causes of cancer-related deaths worldwide. This study is aimed at constructing a risk scoring model based on necroptosis-related miRNAs to predict prognosis of LUAD. Expression profile of miRNA in LUAD was downloaded from The Cancer Genome Atlas (TCGA) database. We screened the differentially expressed necroptosis-related miRNAs between LUAD patients and normal samples, thus constructed a seven miRNA-based risk stratification on the basis of the TGCA cohort. This risk stratification was prove to be effective in predicting the overall survival (OS) of patients with LUAD. Furthermore, we constructed a nomogram model based on the combination of risk characteristics and clinicopathological features, which was also prove to be accurate and efficient in predicting OS of LUAD patients. Functional enrichment analyses on the targeted genes of these miRNAs with prognostic value were carried out. Results indicated that these targeted genes were closely related to the development and metastasis of tumors. In summary, our research has developed a prognostic model based on the expression of miRNAs related to necroptosis. This model might be used to predict the prognosis of LUAD accurately, which might be helpful in improving treatment efficacy of LUAD.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flow diagram of the study.
Figure 2
Figure 2
Differentially expressed necroptosis-related miRNAs. (a) A volcano plot of expression change comparing the tumor and normal samples, with the seven downregulated and upregulated miRNAs. (b) The notably differentially expressed necroptosis-related miRNA in each biological specimen from TCGA LUAD cohort were displayed by heat map.
Figure 3
Figure 3
Construction of the prognostic signature based on the TCGA discovery cohort. (a) The distribution of risk scores. (b) The distribution of OS and OS status in the high- and low-risk score groups. (c) The distribution of OS and OS status in the high- and low-risk groups. (d) Kaplan–Meier curves for the OS of patients in the high- and low-risk groups.
Figure 4
Figure 4
Univariate and multivariate Cox regression analyses for the risk score. (a) Univariate analysis for the TCGA cohort. (b) Multivariate analysis for the TCGA cohort. (c) Heatmap of clinicopathological characteristics of the low- and high-risk patients.
Figure 5
Figure 5
Integrated prognostic nomogram by combining risk signature and clinicopathological features. (a) A nomogram predicting 3- and 5-year OS of LUAD. (b) The calibration plots demonstrated that the nomogram showed excellent performance for predicting the 3-year OS. (c) The calibration plots demonstrated that the nomogram showed excellent performance for predicting the 5-year OS.
Figure 6
Figure 6
Functional annotation of the risk signature. (a) Venn diagram for the shared genes among three online databases. (b) The results of GO enrichment analysis. (c) The results of KEGG pathway analysis.
See this image and copyright information in PMC

References

    1. Nasim F., Sabath B. F., Eapen G. A. Lung cancer. The Medical Clinics of North America . 2019;103(3):463–473. doi: 10.1016/j.mcna.2018.12.006. - DOI - PubMed
    1. Sung H., Ferlay J., Siegel R. L., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians . 2021;71(3):209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Bade B. C., Dela Cruz C. S. Lung cancer 2020: epidemiology, etiology, and prevention. Clinics in Chest Medicine . 2020;41(1):1–24. doi: 10.1016/j.ccm.2019.10.001. - DOI - PubMed
    1. Zhang H. M., Yang B., Chen H. F., et al. Prognosis-related miRNA bioinformatics screening of lung adenocarcinoma and its clinical significance. Chinese Journal of Applied Physiology . 2018;34(6):530–535. doi: 10.12047/j.cjap.5755.2018.118. - DOI - PubMed
    1. Inamura K., Ishikawa Y. MicroRNA in lung cancer: novel biomarkers and potential tools for treatment. Journal of Clinical Medicine . 2016;5(3):p. 36. doi: 10.3390/jcm5030036. - DOI - PMC - PubMed